News
NWBO
0.200
-0.25%
-0.001
Weekly Report: what happened at NWBO last week (0406-0410)?
Weekly Report · 3d ago
Northwest Biotherapeutics Completes Advent BioServices Acquisition Deal
TipRanks · 04/07 16:57
Northwest Bio completes acquisition of UK CDMO Advent BioServices for $1.9 million
Reuters · 04/07 16:31
Weekly Report: what happened at NWBO last week (0330-0403)?
Weekly Report · 04/06 09:45
Northwest Biotherapeutics Delays Annual SEC Filing
TipRanks · 04/01 01:52
Northwest BioTherapeutics delays annual report filing on Advent BioServices accounting issues
Reuters · 03/31 21:05
Weekly Report: what happened at NWBO last week (0323-0327)?
Weekly Report · 03/30 09:45
First Berlin sets USD 1 price target on Northwest Biotherapeutics
Reuters · 03/24 15:02
First Berlin Equity Research sets USD 1 price target on Northwest Biotherapeutics
Reuters · 03/24 13:39
Weekly Report: what happened at NWBO last week (0316-0320)?
Weekly Report · 03/23 09:43
Weekly Report: what happened at NWBO last week (0309-0313)?
Weekly Report · 03/16 09:42
Weekly Report: what happened at NWBO last week (0302-0306)?
Weekly Report · 03/09 09:44
Weekly Report: what happened at NWBO last week (0223-0227)?
Weekly Report · 03/02 09:43
Weekly Report: what happened at NWBO last week (0216-0220)?
Weekly Report · 02/23 09:43
Weekly Report: what happened at NWBO last week (0209-0213)?
Weekly Report · 02/16 09:42
Weekly Report: what happened at NWBO last week (0202-0206)?
Weekly Report · 02/09 09:44
Weekly Report: what happened at NWBO last week (0126-0130)?
Weekly Report · 02/02 09:43
Weekly Report: what happened at NWBO last week (0119-0123)?
Weekly Report · 01/26 09:44
Weekly Report: what happened at NWBO last week (0112-0116)?
Weekly Report · 01/19 09:47
Northwest Biotherapeutics Reaches Settlement Over 2020 Stock Options
TipRanks · 01/15 22:29
More
Webull provides a variety of real-time NWBO stock news. You can receive the latest news about Northwest Bio through multiple platforms. This information may help you make smarter investment decisions.
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.